Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...
Boston, Dec. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Global Viral Vector Manufacturing Markets and Technologies Through 2030” is projected to grow from $6.3 ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
(MENAFN- EIN Presswire) EINPresswire/ -- "The landscape of viral vector development services is witnessing rapid expansion as gene and cell therapies gain traction worldwide. This sector plays a ...
Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...
Viral vector service expansion empowers scientists by offering high-quality research reagents through on-demand AAV production from Addgene’s vast plasmid repository Addgene, a purpose-driven ...
Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, today announced the expansion of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results